Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter Financial Results

by NASDAQ Market News November 6, 2019

NASDAQ Market News
Click here to email author

Teneobio’s Lead Candidate, TNB-383B, Receives Orphan Drug Designation from the FDA for the Treatment of Multiple Myeloma

Trillium Therapeutics to Report Preclinical Data on Its STING Program at the SITC 34th Annual Meeting

Ads